{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 42,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 120,
  "notes": "The table lists 15 specific adverse events plus 'Any AE' across 4 cohorts, with two columns per cohort (All grades, Grade >=3).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/28",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.06,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Ranked by all grades for the 150mg dose, ≥10% in any arm, irrespective of causality assessment. AE: adverse event; CTCAE: common terminology criteria for adverse events; SD: standard deviation; TEAE: treatment-emergent adverse event; TRAE: treatment-related adverse event",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26b0a196-9cd7-4847-9ab4-ced2a4aa7f3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.93,
        "x": 0.06,
        "y": 0.17
      },
      "kind": "table",
      "text": "Table showing AE counts and percentages for C 75, C 150, C 300, and F 500 cohorts.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94a13363-73dd-4ca9-8d30-6ac3430b9193",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "SERENA-2: all treatment-emergent adverse events",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa45ddf9-407b-4649-981c-51cbd36577f8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "476479dd-c8eb-44b0-b1be-1a5d1525422d",
      "evidence": "table/data: Table showing AE counts and percentages for C 75, C 150, C 300, and F 500 cohorts.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 19,
      "beatId": "a90ff87c-6a94-47ae-8622-c8e4ab68f4ea",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "SERENA-2 trial data and conclusions",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}